Skip to main content

Advertisement

SpringerLink
Log in

Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM)

Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The study aimed to assess factors affecting survival of breast cancer patients suffering leptomeningeal metastasis (LM) and to compare survivals in patients with LM as the first and only site of metastases at presentation to patients with LM and metastases in other organs, along with selecting a patient group which had the best survival outcomes. Subject groups consisted of 187 patients consecutively referred during 1999–2015. A Cox proportional hazards model was used to identify factors associated with prolonged survival from LM. The Cox prognostic index was created to identify the group of patients with the most favorable prognosis. Median survival for all patients and for those with LM as the first site of metastases at presentation was 17 weeks and 1 year-survival was 15 and 16%, respectively. Factors beneficially affecting survival were: KPS ≥ 70, older age, biological subtype ER/PR+HER2−, systemic treatment, intrathecal treatment and radiation therapy. Based on these factors, 4 prognostic groups were found, with the most favorable group being 24 LM patients with median survival of 9.6 months. In this group, all patients were treated systemically and all were irradiated, 88% had KPS ≥ 70, about 80% had luminal breast cancer, 75% were treated intrathecally and 58% were more than 53 years old. Out of 4 prognostic groups of patients with LM, the most favorable group was selected. The median survival of breast cancer patients with the leptomeninges as the only site of metastases was comparable to those who had metastases in the leptomeninges and in other organs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Le Rhun E, Taillibert S, Zairi F et al (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 113:83–92. https://doi.org/10.1007/s11060-013-1092-8

    Article  PubMed  Google Scholar 

  2. Wasserstrom WR, Glass P, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772

    Article  CAS  PubMed  Google Scholar 

  3. Boogerd W, Hart AMH, van der Sande JJ, Engelsman E (1991) Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67:1685–1695

    Article  CAS  PubMed  Google Scholar 

  4. Rudnicka H, Niwińska A, Murawska M (2007) Breast cancer leptomeningeal metastasis—the role of multimodality treatment. J Neurooncol 84:57–62

    Article  PubMed  Google Scholar 

  5. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palange T et al (1996) Meningeal carcinomathosis in patients with breast carcinoma. Clinical features, prognostic factors and results of high-dose intrathecal methotrexate regimen. Cancer 77:1315–1323

    Article  CAS  PubMed  Google Scholar 

  6. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH et al (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21:2183–2187. https://doi.org/10.1093/annonc/mdq232

    Article  CAS  PubMed  Google Scholar 

  7. de Azevedo CRA, Cruz MRS, Chinen LTD, Peres SV, Peterlevitz MA, de Azevedo Pereira AE et al (2011) Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol 104:565–572. https://doi.org/10.1007/s11060-010-0524-y

    Article  PubMed  Google Scholar 

  8. Jo J-C, Kang MJ, Kim JE et al (2013) Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience. Cancer Chemother Pharmacol 72:201–207. https://doi.org/10.1007/s00280-013-2185-y

    Article  CAS  PubMed  Google Scholar 

  9. Hyun J-W, Jeong IH, Joung AR et al (2016) Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer 56:107–114. https://doi.org/10.1016/j.ejca.2015.12.021

    Article  PubMed  Google Scholar 

  10. Le Rhun E, Taillibert S, Chamberlain MC (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 4:S265–S288. https://doi.org/10.4103/2152-7806.111304

    Article  PubMed  PubMed Central  Google Scholar 

  11. Scott BJ, Oberheim-Bush NA, Kesari S (2016) Leptomeningeal metastasis in breast cancer—a systematic review. Oncotarget 7:3740–3747. https://doi.org/10.18632/oncotarget.5911

    PubMed  Google Scholar 

  12. Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance if intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 40:2726–2733

    Article  CAS  PubMed  Google Scholar 

  13. Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison if intraventricular methotrexate and thiothepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561–569

    Article  CAS  PubMed  Google Scholar 

  14. Hitchins RN, Bell DR, Woods RL et al (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomathosis. J Clin Oncol 5:1655–1662

    Article  CAS  PubMed  Google Scholar 

  15. Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402

    CAS  PubMed  Google Scholar 

  16. Shapiro WR, Johanson CE, Boogerd W (2009) Treatment modalities for leptomeningeal metastases. Semin Oncol 36:S46–S54. https://doi.org/10.1053/j.seminoncol.2009.05.006

    Article  CAS  PubMed  Google Scholar 

  17. Shapiro WR, Schmid M, Glantz M et al (2006) A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24:1528

    Article  Google Scholar 

  18. Niwińska A, Rudnicka H, Murawska M (2013) Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol 30(1):408. https://doi.org/10.1007/s12032-012-0408-4

    Article  PubMed  PubMed Central  Google Scholar 

  19. Niwińska A, Rudnicka H, Murawska M (2015) Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy. Clin Breast Cancer 15:66–72. https://doi.org/10.1016/j.clbc.2014.07.004

    Article  PubMed  Google Scholar 

  20. Lara-Medina F, Crismatt A, Villareal-Garza C et al (2012) Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J 18:233–241. https://doi.org/10.1111/j.1524-4741.2012.01228.x

    Article  PubMed  Google Scholar 

  21. Torrejon D, Oliveira M, Cortes J et al (2013) Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast 22:19–23. https://doi.org/10.1016/j.breast.2012.10.009

    Article  PubMed  Google Scholar 

  22. Morikawa A, Jordan L, Rozner R et al (2017) Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer 17:23–28. https://doi.org/10.1016/j.clbc.2016.07.002

    Article  PubMed  Google Scholar 

  23. Meattini I, Livi L, Saieva C et al (2012) Prognostic factors and clinical features in patients with leptomeningeal metastases from breast cancer: a single center experience. J Chemother 24:279–284. https://doi.org/10.1179/1973947812Y.0000000034

    Article  PubMed  Google Scholar 

  24. Le Rhun E, Taillibert S, Zairi F et al (2013) Prolonged survival of patients with breast cancer-related leptomeningeal metastases. Anticancer Res 33:2057–2064

    PubMed  Google Scholar 

  25. Jayson GC, Howell A (1996) Carcinomatous meningitis in solid tumorurs. Ann Oncol 7:773–786

    Article  CAS  PubMed  Google Scholar 

  26. Chamberlain MC, Glantz M, Groves MD et al (2009) Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 36:S35-45. https://doi.org/10.1053/j.seminoncol.2009.05.005

    Article  PubMed  Google Scholar 

  27. Chamberlain MC, Johnston SK, Glantz MJ (2009) Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 66:74–78. https://doi.org/10.1001/archneurol.2008.506

    Article  PubMed  Google Scholar 

  28. Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W et al (2011) Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 129:809–817. https://doi.org/10.1007/s10549-011-1682-0

    Article  PubMed  Google Scholar 

  29. Sacco K, Muhammad A, Saleem W et al (2016) Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer (Review). Oncol Lett 12:779–782

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Breast Cancer and Reconstructive Surgery, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgen 5 Str., 02-781, Warsaw, Poland

    Anna Niwińska, Katarzyna Pogoda, Michał Kunkiel & Agnieszka Jagiełło-Gruszfeld

  2. Bioinformatics and Biostatistics Unit, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781, Warsaw, Poland

    Wojciech Michalski

Authors
  1. Anna Niwińska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katarzyna Pogoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wojciech Michalski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michał Kunkiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Agnieszka Jagiełło-Gruszfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Niwińska.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niwińska, A., Pogoda, K., Michalski, W. et al. Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM). J Neurooncol 138, 191–198 (2018). https://doi.org/10.1007/s11060-018-2790-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-018-2790-z

Keywords

Search

Navigation